Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PARP inhibitors
Pharma
J&J PARP path unclear in castration-sensitive prostate cancer subset
Despite the positive readout from the phase 3 Amplitude trial, uncertainty lies in a group of patients without BRCA mutations.
Angus Liu
Jun 3, 2025 8:00am
J&J, Pfizer and Roche face FDA questions over data applicability
May 16, 2025 3:52pm
Pfizer details survival win in bid for broad prostate cancer nod
Feb 13, 2025 10:00am
GSK trial result mirrors Merck's problem in ovarian cancer
Dec 20, 2024 10:46am
Pfizer targets broad Talzenna label in prostate cancer
Oct 10, 2024 10:18am
ESMO: GSK's Zejula, pharma&'s Rubraca-Opdivo combo disappoint
Sep 14, 2024 8:45am
